GlaxoSmithKline unveil revised executive wages

Pharmaceuticals giant GlaxoSmithKline today bowed to shareholder pressure and unveiled revised pay and rewards contracts for executives.

It scrapped the two-year rolling contracts for executive directors that had sparked investor anger earlier this year over “fat cat” pay, replacing them with a single year deal without compensation.